TORONTO, June 7, 2024
/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS)
announces voting results from its Annual Meeting of Shareholders
held in a virtual format on June 7,
2024.
A total of 21,098,254 Common Shares, or 66.32% of the total
Common Shares issued and outstanding, were voted based on proxies
and votes received at the meeting. Details of the voting by
individual director were as follows:
|
Name of
Nominee
|
Votes
Cast
FOR
|
% of Vote Cast
FOR
|
Votes
WITHHELD
|
% of Votes
WITHHELD
|
|
John Welborn
|
18,209,962
|
88.85
|
2,284,420
|
11.15
|
|
Craig
Millian
|
19,959,739
|
97.39
|
534,643
|
2.61
|
|
John Hanna
|
19,135,935
|
93.37
|
1,358,447
|
6.63
|
|
Rodney Hill
|
19,959,554
|
97.39
|
534,828
|
2.61
|
|
Laura Brege
|
19,118,129
|
93.28
|
1,376,253
|
6.72
|
|
Norma
Beauchamp
|
16,442,226
|
80.23
|
4,052,156
|
19.77
|
|
Kyle Dempsey
|
19,032,703
|
92.87
|
1,461,679
|
7.13
|
|
Christian
Roy
|
19,135,933
|
93.37
|
1,358,449
|
6.63
|
HLS also confirms that shareholders approved the appointment of
Ernst & Young LLP as the Company's auditors with 21,098,117
votes (100%) cast "for" and 137 votes (0%) withheld.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the
acquisition and commercialization of late-stage development,
commercial stage promoted and established branded pharmaceutical
products in the North American markets. HLS's focus is on products
targeting the central nervous system and cardiovascular therapeutic
areas. HLS's management team is composed of seasoned pharmaceutical
executives with a strong track record of success in these
therapeutic areas and at managing products in each of these
lifecycle stages. For more information visit:
www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.
